Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.67 |
| ▸ | PDE2A | O00408 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394457 | 0.94 | SPR (0.68) | SPRPDE2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3390170 | 0.94 | SPR (0.68) | SPRPDE2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2854682 | 0.85 | ALDH1A1 (0.60) | SPRPDE2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2857348 | 0.84 | SPR (0.54) | SPRPDE2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3395175 | 0.84 | SPR (0.62) | SPRNPC1RAB9APKMTAS1R3 | |
| SCHEMBL3392887 | 0.84 | SPR (0.62) | SPRNPC1RAB9APKMTAS1R3 | |
| SCHEMBL3394452 | 0.82 | RAB9A (0.52) | NPC1RAB9APKMHPGDHSD11B1 | |
| SCHEMBL3390165 | 0.82 | RAB9A (0.52) | NPC1RAB9APKMHPGDHSD11B1 | |
| SCHEMBL18703568 | 0.80 | SPR (1.00) | SPR | |
| SCHEMBL2079208 | 0.80 | RAB9A (0.57) | NPC1RAB9APKMHPGDHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373191-B1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-06-05 | — | — | EP | claimed |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-22 | — | — | US | claimed |
| US-7713963-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-11 | — | — | US | claimed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | claimed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | claimed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | claimed |
| EP-1373191-B1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-8163751-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-7713963-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7179839-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | SPR 2185/4885PDE2A 77/4885NPC1 633/4885 |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | EDNRA, VEGFA, EDNRB | SPR 3013/4885PDE2A 83/4885NPC1 355/4885 |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | SPR 2290/4885PDE2A 72/4885NPC1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.